The clinical development of glycosylase-engineered base editors (C-to-G transversion editors), dual-editor delivery systems, and integration with prime editing architectures defines the future scope of the Base Editing Market. Expanding editing capabilities beyond transition mutations (C-to-T, A-to-G) to include transversion conversions (C-to-G, A-to-C) unlocks targetability for thousands of...